Stockscreener 앱 받기
0.00
100.00%
-0.0941
전일 마감가:
$0.0941
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$5.67M
수익:
$7.10M
순이익/손실:
$-31.59M
주가수익비율:
0.00
EPS:
-2.61
순현금흐름:
$-26.75M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.215
52주 변동 폭
$0.00
$2.48
Palatin Technologies Inc. Stock (PTN) Company Profile
명칭
Palatin Technologies Inc.
전화
609-495-2200
주소
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
PTN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.00 | 5.67M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-06-05 | 재확인 | Canaccord Genuity | Buy |
| 2015-01-12 | 재확인 | ROTH Capital | Buy |
| 2012-05-23 | 개시 | Noble Financial | Buy |
| 2007-01-23 | 개시 | Next Generation | Buy |
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com South Africa
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - Longview News-Journal
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Technologies Announces Closing of Reduced Public Offering - Stock Titan
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Stock Titan
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa
Palatin Prices $11.5 Mln Public Offering - Nasdaq
Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq
Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com
Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com
Palatin (PTN) Aims to Address Delisting Concerns with Public Offering | PTN Stock News - GuruFocus
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Canada
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering | PTN Stock News - GuruFocus
Palatin Technologies sets terms for $23 million offering - Investing.com
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Cand - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Ago - GuruFocus
Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment - Nasdaq
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy - GuruFocus
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Candidate PL9588 | PTN Stock News - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy – Company AnnouncementFT.com - Financial Times
Palatin Technologies (NYSE:PTN) Coverage Initiated at StockNews.com - Defense World
After The Stock Rose 2.56% Over The Week, Is Palatin Technologies Inc (AMEX: PTN) Still A Buy? - Marketing Sentinel
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease - The Malaysian Reserve
Palatin Announces Breakthrough Symptom Resolution in Updated Ana - GuruFocus
Palatin (PTN) Announces Promising Results for PL9643 in Dry Eye Disease Study | PTN Stock News - GuruFocus
Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED - Nasdaq
First-Ever Complete Symptom Resolution: Game-Changing Phase 3 Results in $6B Dry Eye Market - Stock Titan
Market Resilience: Palatin Technologies Inc (PTN) Finishes Weak at 0.66, Down -5.41 - DWinneX
The Attractiveness of Investing In Palatin Technologies Inc (PTN) is Growing - knoxdaily.com
Trading Day Triumph: Palatin Technologies Inc (PTN) Ends at 0.21, a -1.24 Surge/Plunge - DWinneX
Investor Network: Palatin Technologies, Inc. to Host Earnings Call - ACCESS Newswire
Palatin Technologies (NYSE:PTN) Now Covered by StockNews.com - Defense World
NYSE to Commence Delisting Proceedings Against Solo Brands, Inc. (DTC) - Business Wire
A Guide To The Risks Of Investing In Palatin Technologies Inc (PTN) - knoxdaily.com
Palatin Technologies Inc’s Banking’s 100-Day Moving Average at 0.8728: Will the Stock Break Through? - investchronicle.com
StockNews.com Begins Coverage on Palatin Technologies (NYSE:PTN) - Defense World
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Palatin Technologies Inc. (PTN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):